Download Citation on ResearchGate | Clonixinato de lisina mg versus diclofenac 75 mg en el tratamiento del dolor cólico renal Ensayo clínico prospectivo. MASTER FARMA S.A., MEDICINA, PRODUCTOS, DORIXYL – CLONIXINATO DE LISINA, antiinflamatorios, los antiinflamatorios no esteroideos, impidiendo la. Many translated example sentences containing “clonixinato de lisina” – English- Spanish dictionary and search engine for English translations.

Author: Voshicage Tosar
Country: Philippines
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 28 January 2011
Pages: 86
PDF File Size: 8.87 Mb
ePub File Size: 17.89 Mb
ISBN: 902-5-65243-976-8
Downloads: 87928
Price: Free* [*Free Regsitration Required]
Uploader: Faezahn

Krymchantowski 1Jackeline S. Barbosa 1Celia Cheim 1Luiz A. Lysine clonixinate LC is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of oral LC compared to placebo in the acute treatment of migraine. Sixty four patients with the diagnosis of migraine, according to the IHS criteria, were studied prospectively.

Clonixinato de lisina Sanderson

Patients received LC or placebo once the headache reached moderate or severe intensity for 6 consecutive attacks. With regard to the moderate attacks, LC was superior than clonidinato after 1, 2 and 4 hours. The consumption of other rescue medications after 4 hours was significantly higher in the placebo group. With regard to the severe attacks, there clonixniato no difference between the active drug group and the placebo group concerning headache intensity and consumption of other rescue medications.

We conclude that the NSAID lysine clonixinate is effective in treating moderately severe migraine attacks. It is not superior than placebo in treating severe migraine attacks. Para as crises moderadas, o CL foi superior ao placebo em 1, 2 e 4 horas.

Clonixinato de lisina Sanderson –

Migraines are highly prevalent primary headaches that can start in childhood or adolescence 1,2. It affects mostly women and manifests clinically as moderate to severe headache attacks, frequently of unilateral fronto-temporal locations. Headache may last from 4 to 72 llsina when it is not treated or is ineffectively treated. Lsiina of pain occurrence is variable and some patients can have it on a weekly basis, while others will have it less than once a month. There are several drug options for the treatment of acute migraine attacks.

The choice of one or another will depend on pain clomixinato, its frequency and associated symptoms, co-morbidity, progression profile and individual patients response 3. Several patients find pain relief using simple analgesics such as acetyl salicylic acid, acetaminophen, dipirone, mefenamic acid or some combination of these. In fact, a recent multicenter study found that the association of aspirin, acetaminophen and caffeine was efficient to treat most of the acute migraine attacks 4.

Nonsteroidal anti-inflammatory drugs NSAIDs like diclofenac clonixniatonaproxen 6 and ibuprofen 7 also proved to be efficacious in the acute treatment of migraine.

Clonixinato de lisina

It has a chemical structure resembling the flufenamic acid, although it is derived from nicotinic acid. Its efficacy in the treatment of acute migraine attacks was suggested by previous non-controlled studies, both in oral 8 as well as in parenteral administration 9. Lysine’s structural formula as 2- 3-chloro-o-toluidine piridinocarboxilate allows a fast absorption 10 and its inhibiting effect on the enzyme cyclooxygenase, important in prostaglandin synthesis, is reversible.


The aim of this study was to evaluate the efficacy of oral lysine clonixinate compared to placebo in the treatment of acute migraine. We studied 64 patients with migraine, prospectively diagnosed according to the criteria of the International Headache Society IHS Fifty five were women and 9 were men, aged from 18 to 53 years.

Patients were randomized and divided into two groups A and Bwhich received placebo or CL. Regardless of pain intensity, another tablet of LC or placebo had to be taken 40 minutes later by all patients. Patients were instructed to record in a diary their pain intensity just prior to taking the medication, and 1, 2 and 4 hours later.

The patients also recorded the occurrence of vomiting after the drug ingestion and the consumption of other rescue medications after 4 hours. Group A included 31 patients, who had moderate and 34 severe attacks, and were treated with placebo. Vomiting occurred in 11 of the moderate and 7 of the severe attacks. Thirty three patients in group B having moderate and 48 severe attacks were treated with lysine clonixinate.

Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

Vomiting followed the ingestion of the medication in 8 moderate and in cllnixinato severe attacks. With regard to the treatment of moderate attacks, After 2 hours, After 4 hours, With regard to the severe attacks, after 1h, Figure 4 shows that Lysine clonixinate 2- 3-chlorotoluidine piridinlysine carboxilate is a NSAID effective in the treatment of several pain syndromes such as renal colic, nerve entrapment pain, muscular pain and tooth ache 10,12, The efficacy of other NSAIDs in the acute treatment of migraine, as well as that of lysine clonixinate, have been demonstrated in previous studies This study confirms the efficacy of se clonixinate compared to placebo in reducing both intensity and duration of moderate migraine attacks, as well as the consumption of rescue medications after 4 hours.

The speed of action of lysine clonixinate is favorable and can’t be compared with that of ibuprofen 7diclofenac 5tolfenamic acid 14NSAID also demonstrated as being efficient in the acute clonoxinato of migraine, since the methodology and design of this study, when the patients took cloniixinato capsule 40 minutes later, was unique and not done with the above mentioned NSAID.

LC also has been proven effective after 1 hour in moderate attacks. However comparative cllnixinato with regard to early efficacy of both drugs can’t be accomplished due to different study designs, methods and patient selection.

Nonsteroidal anti-inflammatory drugs seem to act clonoxinato inhibition of prostaglandin synthesis and platelet aggregation as well as the inhibition of serotonin release from platelets Despite its efficacy and fast speed of action in many types of pain syndromes, it has been shown that lysine clonixinate also has a central clonixinao action, specifically in the thalamus and lksina cord 10, Sierralta 12 have demonstrated an interaction between lysine clonixinate and the central serotoninergic system.

Lysine clonixinate was not superior to placebo in reducing the intensity and duration of severe headaches, nor the consumption of rescue medications after 4 hours. Which sites of action were important in obtaining the results achieved in moderate attacks remains uncertain. Remission clomixinato the pain probably resulted from association of all those mechanisms of action and the reason why it failed to control severe attacks is unknown.


Based upon pharmacokinetics of triptans, efficient drugs employed in the treatment of the acute migraine attack, it is suggested that it is important to penetrate the blood-brain barrier in order to obtain a rapid and prolonged effect That is observed with lysine clonixinate 10,12, Headache recurrence, defined as the return of the headache within 24 hours after it has become mild or absent, may occur with triptans 17,20 and other headache drugs and should be studied with this Clonixinago.

It is also necessary to evaluate the possibility of using lysine clonixinate in patients with ischaemic coronary artery disease and uncontrolled hypertension in whom triptans are contraindicated, as well as in patients with history of peptic disease in whom NSAIDs are contraindicated. The authors have not observed any significant side effects using LC, losina nausea, vomiting, allergic reactions, postural hypotension, vertigo and insomnia have been described in the literature 8,9, This study indicates that oral administration of mg lysine clonixinate followed by another mg tablet 40 minutes later, is efficient and well tolerated in the treatment of moderate attacks of migraine.

The authors would not recommend its use in severe attacks of migraine. Acknowledgements – The authors thank Dr. Alan Rapoport for reviewing the manuscript and emphasize that this study did not receive clnixinato financial support.

Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Efficacy and safety of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating headache pain of an acute migraine attack: Dahlof C, Bjorkman R.

Diclofenac-K 50 and mg and placebo in the acute treatment of liskna. Treatment of acute migraine attack: A double-blind study of ibuprofen versus placebo in the tratment of acute migraine attacks.

Clonixinato de lisina no tratamento de enxaquecas. RBM ; Krymchantowski A, Barbosa J. Comparacion del efecto analgesico del clonixinato de lisina com un hipno-analgesico. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia ;8 Suppl 7: Proceedings of the 9 th Latinoamerican Congress of Pharmacology and Therapeutics.

The clonixinao of intravenous lysine clonixinate for rapid pain relief: Curr Therap Res ; Tolfenamic acid is as effective as ergotamine during migraine attacks. Sumatritpan in clinical practice: International C90 Cloixinato Study Group. The Long-term tolerability and efficacy of oral zolmitriptan Zomig C90 in the acute treatment of migraine: Acute migraine attack therapy: Received 2 Augustreceived in final form 21 September Accepted 26 September FAX 55 21 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.

Services on Demand Journal. How to cite this article.

Author: admin